Adiposity and Airway Inflammation in HIV-Associated Airway Disease
NCT ID: NCT02975258
Last Updated: 2017-10-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
102 participants
Study Classification
OBSERVATIONAL
Study Start Date
2015-09-30
Study Completion Date
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goals of this study are to 1) examine the relationships among inflammation, obesity, and asthma in people with HIV and 2) to test if special subtypes of cells or markers are present in the blood and lungs of people with HIV with asthma compared to those without asthma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The proposed study involves the recruitment of participant population and the use of data from the existing research study cohorts that have been recruited and have provided informed consent for participation. Participants meet all inclusion/exclusion criteria will be enrolled into the study. Participants in the existing research study cohorts have pulmonary function testing, chest CT scans, and blood draws at each study visit which occurs every 18 months for 3 visits. Some of the study procedures may not be repeated if they were done as part of other research projects.
1. Main study visit
The following research procedures may be performed over the course of one or more visits to accommodate scheduling needs. The study visit will take place at the Montefiore Clinical and Translational Research Center and the University of Pittsburgh Asthma Institute in the University of Pittsburgh Medical Center - Montefiore Hospital and may take up to 4 hours to complete.
* Informed consent
* Medical history review and demographics
* Review of inclusion/exclusion criteria
* Physical examination to include vital signs, weight and height, waist, hip, and thigh circumferences.
* Urine pregnancy test for female of childbearing potential
* Asthma-focused and quality of life questionnaire
* Exhaled Nitric Oxide (eNO) measurement
* Spirometry
* Methacholine challenge testing - will not need to be repeated if the participant had done this as part of another study in the past 6 months.
* Chest/Abdominal CT scans (If the participant has had the Chest CT scan done within 6 months as part of other research study, they will not be repeated for study purposes. Only the Abdominal CT will be performed)
* Research blood sampling for biomarker analyses - some of this blood will also be used for pre-bronchoscopy testing in the case that the participant qualifies and is interested in undergoing part 2, the bronchoscopy visit.
* Adipose tissue biopsy (Fat Biopsy): performed on participants with a BMI≥25). This will be repeated if done previously because testing to be done on the fat will be different than what had been tested on the fat previously.
2. Optional sub-study
On a separate visit, only a subset of 60 selected participants will be asked to undergo the following procedures to obtain additional lung biological samples. This visit is optional for participants who are willing to participate in the bronchoscopy portion. The investigators will try to recruit an equal number (n=15 per group) of obese asthmatics, obese non-asthmatics, non-obese asthmatics, and non-obese non-asthmatics. The visit will take place in the Montefiore Clinical Translational Research Center (MUH-CTRC). The bronchoscopy procedure will take about 30-45 minutes, but the preparation and recovery time will usually make the visit about 4-8 hours total.
Participants will be expected to fast for 8 hours prior to the bronchoscopy procedure and refrain from drinking any liquids the day of the procedure. Participants may take their usual medicines with sips of water.
• Clinical laboratory testing to include complete blood count/differential/platelet count, prothrombin time/partial thromboplastin time, international Normalized Ratio, blood urea nitrogen, and creatinine prior to bronchoscopy. If the patient refuses the first blood draw, the sample is inadequate, or the labs were run more than 30 days prior to the bronchoscopy visit, a second blood sample of up to 1 tablespoon may be drawn prior to the bronchoscopy procedure to ensure the patient is healthy enough for the procedure.
If Methacholine challenge was done more than 30 days prior to the visit two date, pulmonary function tests will be repeated.
* Oral Wash: participants will be asked to gargle with salt water for 1 minute and then spit into a container to provide a sample of approximately 10mls (2 teaspoons) at this study visit.
* Tongue Scraping: tongue blade or similar object will be used to scrape the participant's tongue. This sample will be used to determine what bacteria are on the participant's tongue. This procedure should only take minutes and is not painful.
* Participants will then rinse with 10cc's of Listerine. This is to assure that there are no bacteria left behind in the participant's mouth prior to the bronchoscopy.
* Bronchoscopy with bronchoalveolar lavage (BAL), endobronchial brushing and biopsy
Under local anesthesia, participants will undergo bronchoscopy with BAL for microbiologic specimens. A light intravenous anesthetic will be titrated to provide participant comfort if necessary. Vitals signs will be monitored continuously before, during, and after the procedure. This procedure consists of 3 stages.
1. Pulmonary Lavage: During pulmonary lavage, five 50 mL washes of sterile salt-water solution will be injected through the bronchoscope. Fluid will be collected with gentle suctioning for research studies.
2. Bronchial Brushing: A small brush will be introduced through the bronchoscope and gently rubbed over a very small part of the surface of the lungs. Approximately 10 brushes will be performed to collect epithelial cells.
3. Endobronchial Biopsy: While the bronchoscope is inserted, another small instrument will be passed through the bronchoscope to take small samples (biopsies) of tissue from the walls of the airways. Up to 5 samples may be taken during this procedure.
Following the bronchoscopy procedure, participants will be closely monitored in the bronchoscopy recovery area or return to the CTRC. Rarely, the participant's asthma may worsen during or after the procedure. Appropriate medical treatments or overnight observation will be provided if needed. Participants will not be allowed to drive home after the bronchoscopy. This is because the sedatives used during the procedure may decrease driving ability. The investigators will ask for the contact name and number of the person that will pick up the participant after the bronchoscopy
1. Main study visit
The following research procedures may be performed over the course of one or more visits to accommodate scheduling needs. The study visit will take place at the Montefiore Clinical and Translational Research Center and the University of Pittsburgh Asthma Institute in the University of Pittsburgh Medical Center - Montefiore Hospital and may take up to 4 hours to complete.
* Informed consent
* Medical history review and demographics
* Review of inclusion/exclusion criteria
* Physical examination to include vital signs, weight and height, waist, hip, and thigh circumferences.
* Urine pregnancy test for female of childbearing potential
* Asthma-focused and quality of life questionnaire
* Exhaled Nitric Oxide (eNO) measurement
* Spirometry
* Methacholine challenge testing - will not need to be repeated if the participant had done this as part of another study in the past 6 months.
* Chest/Abdominal CT scans (If the participant has had the Chest CT scan done within 6 months as part of other research study, they will not be repeated for study purposes. Only the Abdominal CT will be performed)
* Research blood sampling for biomarker analyses - some of this blood will also be used for pre-bronchoscopy testing in the case that the participant qualifies and is interested in undergoing part 2, the bronchoscopy visit.
* Adipose tissue biopsy (Fat Biopsy): performed on participants with a BMI≥25). This will be repeated if done previously because testing to be done on the fat will be different than what had been tested on the fat previously.
2. Optional sub-study
On a separate visit, only a subset of 60 selected participants will be asked to undergo the following procedures to obtain additional lung biological samples. This visit is optional for participants who are willing to participate in the bronchoscopy portion. The investigators will try to recruit an equal number (n=15 per group) of obese asthmatics, obese non-asthmatics, non-obese asthmatics, and non-obese non-asthmatics. The visit will take place in the Montefiore Clinical Translational Research Center (MUH-CTRC). The bronchoscopy procedure will take about 30-45 minutes, but the preparation and recovery time will usually make the visit about 4-8 hours total.
Participants will be expected to fast for 8 hours prior to the bronchoscopy procedure and refrain from drinking any liquids the day of the procedure. Participants may take their usual medicines with sips of water.
• Clinical laboratory testing to include complete blood count/differential/platelet count, prothrombin time/partial thromboplastin time, international Normalized Ratio, blood urea nitrogen, and creatinine prior to bronchoscopy. If the patient refuses the first blood draw, the sample is inadequate, or the labs were run more than 30 days prior to the bronchoscopy visit, a second blood sample of up to 1 tablespoon may be drawn prior to the bronchoscopy procedure to ensure the patient is healthy enough for the procedure.
If Methacholine challenge was done more than 30 days prior to the visit two date, pulmonary function tests will be repeated.
* Oral Wash: participants will be asked to gargle with salt water for 1 minute and then spit into a container to provide a sample of approximately 10mls (2 teaspoons) at this study visit.
* Tongue Scraping: tongue blade or similar object will be used to scrape the participant's tongue. This sample will be used to determine what bacteria are on the participant's tongue. This procedure should only take minutes and is not painful.
* Participants will then rinse with 10cc's of Listerine. This is to assure that there are no bacteria left behind in the participant's mouth prior to the bronchoscopy.
* Bronchoscopy with bronchoalveolar lavage (BAL), endobronchial brushing and biopsy
Under local anesthesia, participants will undergo bronchoscopy with BAL for microbiologic specimens. A light intravenous anesthetic will be titrated to provide participant comfort if necessary. Vitals signs will be monitored continuously before, during, and after the procedure. This procedure consists of 3 stages.
1. Pulmonary Lavage: During pulmonary lavage, five 50 mL washes of sterile salt-water solution will be injected through the bronchoscope. Fluid will be collected with gentle suctioning for research studies.
2. Bronchial Brushing: A small brush will be introduced through the bronchoscope and gently rubbed over a very small part of the surface of the lungs. Approximately 10 brushes will be performed to collect epithelial cells.
3. Endobronchial Biopsy: While the bronchoscope is inserted, another small instrument will be passed through the bronchoscope to take small samples (biopsies) of tissue from the walls of the airways. Up to 5 samples may be taken during this procedure.
Following the bronchoscopy procedure, participants will be closely monitored in the bronchoscopy recovery area or return to the CTRC. Rarely, the participant's asthma may worsen during or after the procedure. Appropriate medical treatments or overnight observation will be provided if needed. Participants will not be allowed to drive home after the bronchoscopy. This is because the sedatives used during the procedure may decrease driving ability. The investigators will ask for the contact name and number of the person that will pick up the participant after the bronchoscopy
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Asthma
HIV
Adiposity
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
HIV
Asthma
Adiposity
Lung disease
Weight
Fat
Obese
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood draw
Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
Intervention Type
PROCEDURE
Questionnaires
The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
Intervention Type
OTHER
Spirometry
Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
Intervention Type
PROCEDURE
Methacholine challenge test
A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
Intervention Type
PROCEDURE
Quantitative CT scans
There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
Intervention Type
RADIATION
Urine pregnancy test
All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
Intervention Type
PROCEDURE
Adipose biopsy
The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin \& into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
Intervention Type
PROCEDURE
Exhaled nitric oxide measurement
The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Lung function testing
Asthma Test
CT scan of the chest
CT scan of the abdomen
Fat pad biopsy
Fat biopsy
ENO measurement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. 18 years of age or older
2. Subject who have been previously determined to be HIV positive through testing
2. Subject who have been previously determined to be HIV positive through testing
Exclusion Criteria
1. Pregnancy or breast-feeding
2. Contraindication to pulmonary function testing (i.e. abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.)
3. Heart condition such as tachycardia, angina or arrhythmias
4. Acute respiratory infection: increasing respiratory symptoms or fever (temperature \>100.4°F \[38°C\]) within 4 weeks of study entry
5. Hospitalization within 4 weeks of study entry
6. Uncontrolled hypertension at screening visit (systolic \> 160 mm Hg or diastolic \> 100 mm Hg) from an average of two or more readings (participant may return for screening after blood pressure is controlled)
7. Active cancer requiring systemic chemotherapy or radiation
8. Active infection of lungs, brain, or abdomen; or intravenous drug use or alcohol use that will impair ability to complete study investigations in the opinion of the investigator
9. History of prior lung resection
2. Contraindication to pulmonary function testing (i.e. abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.)
3. Heart condition such as tachycardia, angina or arrhythmias
4. Acute respiratory infection: increasing respiratory symptoms or fever (temperature \>100.4°F \[38°C\]) within 4 weeks of study entry
5. Hospitalization within 4 weeks of study entry
6. Uncontrolled hypertension at screening visit (systolic \> 160 mm Hg or diastolic \> 100 mm Hg) from an average of two or more readings (participant may return for screening after blood pressure is controlled)
7. Active cancer requiring systemic chemotherapy or radiation
8. Active infection of lungs, brain, or abdomen; or intravenous drug use or alcohol use that will impair ability to complete study investigations in the opinion of the investigator
9. History of prior lung resection
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Sponsor Role
collaborator
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Sponsor Role
collaborator
University of Pittsburgh
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alison Morris
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alison Morris, MD, MS
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Gingo MR, Wenzel SE, Steele C, Kessinger CJ, Lucht L, Lawther T, Busch M, Hillenbrand ME, Weinman R, Slivka WA, McMahon DK, Zhang Y, Sciurba FC, Morris A. Asthma diagnosis and airway bronchodilator response in HIV-infected patients. J Allergy Clin Immunol. 2012 Mar;129(3):708-714.e8. doi: 10.1016/j.jaci.2011.11.015. Epub 2011 Dec 15.
Reference Type
BACKGROUND
Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004 Jan;113(1):101-8. doi: 10.1016/j.jaci.2003.10.041.
Reference Type
BACKGROUND
Holguin F, Comhair SA, Hazen SL, Powers RW, Khatri SS, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Fitzpatrick AM, Gaston B, Israel E, Jarjour NN, Moore WC, Peters SP, Teague WG, Chung KF, Erzurum SC, Wenzel SE. An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med. 2013 Jan 15;187(2):153-9. doi: 10.1164/rccm.201207-1270OC. Epub 2012 Nov 29.
Reference Type
BACKGROUND
Gingo MR, George MP, Kessinger CJ, Lucht L, Rissler B, Weinman R, Slivka WA, McMahon DK, Wenzel SE, Sciurba FC, Morris A. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med. 2010 Sep 15;182(6):790-6. doi: 10.1164/rccm.200912-1858OC. Epub 2010 Jun 3.
Reference Type
BACKGROUND
Crothers K, Thompson BW, Burkhardt K, Morris A, Flores SC, Diaz PT, Chaisson RE, Kirk GD, Rom WN, Huang L; Lung HIV Study. HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc. 2011 Jun;8(3):275-81. doi: 10.1513/pats.201009-059WR.
Reference Type
BACKGROUND
Gingo MR, Balasubramani GK, Kingsley L, Rinaldo CR Jr, Alden CB, Detels R, Greenblatt RM, Hessol NA, Holman S, Huang L, Kleerup EC, Phair J, Sutton SH, Seaberg EC, Margolick JB, Wisniewski SR, Morris A. The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts. PLoS One. 2013;8(3):e58812. doi: 10.1371/journal.pone.0058812. Epub 2013 Mar 12.
Reference Type
BACKGROUND
Grubb JR, Moorman AC, Baker RK, Masur H. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS. 2006 May 12;20(8):1095-107. doi: 10.1097/01.aids.0000226949.64600.f9. No abstract available.
Reference Type
BACKGROUND
Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Munoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B. The changing face of HIV/AIDS in treated patients. Curr HIV Res. 2009 Jul;7(4):365-77. doi: 10.2174/157016209788680633.
Reference Type
BACKGROUND
Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, Oursler KK, Rimland D, Gibert CL, Butt AA, Justice AC. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011 Feb 1;183(3):388-95. doi: 10.1164/rccm.201006-0836OC. Epub 2010 Sep 17.
Reference Type
BACKGROUND
Akinbami LJ, Moorman JE, Bailey C, Zahran HS, King M, Johnson CA, Liu X. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief. 2012 May;(94):1-8.
Reference Type
BACKGROUND
Moorman JE, Zahran H, Truman BI, Molla MT; Centers for Disease Control and Prevention (CDC). Current asthma prevalence - United States, 2006-2008. MMWR Suppl. 2011 Jan 14;60(1):84-6. No abstract available.
Reference Type
BACKGROUND
Gingo MR, Balasubramani GK, Rice TB, Kingsley L, Kleerup EC, Detels R, Seaberg EC, Greenblatt RM, Holman S, Huang L, Sutton SH, Bertolet M, Morris A. Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts. BMC Pulm Med. 2014 Apr 30;14:75. doi: 10.1186/1471-2466-14-75.
Reference Type
BACKGROUND
Lehmann S, Bakke PS, Eide GE, Gulsvik A. Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. Respir Med. 2007 Jun;101(6):1183-90. doi: 10.1016/j.rmed.2006.11.007. Epub 2006 Dec 22.
Reference Type
BACKGROUND
Shore SA. Obesity, airway hyperresponsiveness, and inflammation. J Appl Physiol (1985). 2010 Mar;108(3):735-43. doi: 10.1152/japplphysiol.00749.2009. Epub 2009 Oct 29.
Reference Type
BACKGROUND
Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007 Apr 1;175(7):661-6. doi: 10.1164/rccm.200611-1717OC. Epub 2007 Jan 18.
Reference Type
BACKGROUND
Sutherland ER, Lehman EB, Teodorescu M, Wechsler ME; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Body mass index and phenotype in subjects with mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2009 Jun;123(6):1328-34.e1. doi: 10.1016/j.jaci.2009.04.005.
Reference Type
BACKGROUND
Dixon AE, Pratley RE, Forgione PM, Kaminsky DA, Whittaker-Leclair LA, Griffes LA, Garudathri J, Raymond D, Poynter ME, Bunn JY, Irvin CG. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011 Sep;128(3):508-15.e1-2. doi: 10.1016/j.jaci.2011.06.009. Epub 2011 Jul 23.
Reference Type
BACKGROUND
Shore SA, Schwartzman IN, Mellema MS, Flynt L, Imrich A, Johnston RA. Effect of leptin on allergic airway responses in mice. J Allergy Clin Immunol. 2005 Jan;115(1):103-9. doi: 10.1016/j.jaci.2004.10.007.
Reference Type
BACKGROUND
Sood A, Cui X, Qualls C, Beckett WS, Gross MD, Steffes MW, Smith LJ, Jacobs DR Jr. Association between asthma and serum adiponectin concentration in women. Thorax. 2008 Oct;63(10):877-82. doi: 10.1136/thx.2007.090803. Epub 2008 Apr 4.
Reference Type
BACKGROUND
Sood A, Qualls C, Schuyler M, Thyagarajan B, Steffes MW, Smith LJ, Jacobs DR Jr. Low serum adiponectin predicts future risk for asthma in women. Am J Respir Crit Care Med. 2012 Jul 1;186(1):41-7. doi: 10.1164/rccm.201110-1767OC. Epub 2012 Apr 6.
Reference Type
BACKGROUND
Wildman RP, Kaplan R, Manson JE, Rajkovic A, Connelly SA, Mackey RH, Tinker LF, Curb JD, Eaton CB, Wassertheil-Smoller S. Body size phenotypes and inflammation in the Women's Health Initiative Observational Study. Obesity (Silver Spring). 2011 Jul;19(7):1482-91. doi: 10.1038/oby.2010.332. Epub 2011 Jan 13.
Reference Type
BACKGROUND
Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011 Jun;121(6):2111-7. doi: 10.1172/JCI57132. Epub 2011 Jun 1.
Reference Type
BACKGROUND
Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. doi: 10.1172/JCI29069.
Reference Type
BACKGROUND
Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ; Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):434-9. doi: 10.1161/01.ATV.0000058402.34138.11. Epub 2003 Jan 30.
Reference Type
BACKGROUND
Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998 Mar;83(3):847-50. doi: 10.1210/jcem.83.3.4660.
Reference Type
BACKGROUND
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87-91. doi: 10.1126/science.7678183.
Reference Type
BACKGROUND
Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993 Dec 15;268(35):26055-8.
Reference Type
BACKGROUND
Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, McDonnell M, Hess D, Joseph L, Gokce N. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1654-9. doi: 10.1161/ATVBAHA.108.170316. Epub 2008 Jun 19.
Reference Type
BACKGROUND
Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996 Jun 1;97(11):2601-10. doi: 10.1172/JCI118709.
Reference Type
BACKGROUND
Masia M, Padilla S, Garcia N, Jarrin I, Bernal E, Lopez N, Hernandez I, Gutierrez F. Endothelial function is impaired in HIV-infected patients with lipodystrophy. Antivir Ther. 2010;15(1):101-10. doi: 10.3851/IMP1491.
Reference Type
BACKGROUND
Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006 Apr 18;113(15):1888-904. doi: 10.1161/CIRCULATIONAHA.105.563213.
Reference Type
BACKGROUND
Paruthi J, Gill N, Mantzoros CS. Adipokines in the HIV/HAART-associated lipodystrophy syndrome. Metabolism. 2013 Sep;62(9):1199-205. doi: 10.1016/j.metabol.2013.04.014. Epub 2013 May 24.
Reference Type
BACKGROUND
Tong Q, Sankale JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK, Hotamisligil GS. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab. 2003 Apr;88(4):1559-64. doi: 10.1210/jc.2002-021600.
Reference Type
BACKGROUND
Vigouroux C, Maachi M, Nguyen TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003 Jul 4;17(10):1503-11. doi: 10.1097/00002030-200307040-00011.
Reference Type
BACKGROUND
Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo C, Kuller LH, Justice A, Freiberg M. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012 Jul;55(1):126-36. doi: 10.1093/cid/cis406. Epub 2012 Apr 24.
Reference Type
BACKGROUND
Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013 Apr 22;173(8):614-22. doi: 10.1001/jamainternmed.2013.3728.
Reference Type
BACKGROUND
Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Justice AC; Veterans Aging Cohort Study. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):425-32. doi: 10.1161/CIRCOUTCOMES.110.957415. Epub 2011 Jun 28.
Reference Type
BACKGROUND
Justice AC, Braithwaite RS. Lessons learned from the first wave of aging with HIV. AIDS. 2012 Jul 31;26 Suppl 1(Suppl 1):S11-8. doi: 10.1097/QAD.0b013e3283558500.
Reference Type
BACKGROUND
Sattler FR, He J, Letendre S, Wilson C, Sanders C, Heaton R, Ellis R, Franklin D, Aldrovandi G, Marra CM, Clifford D, Morgello S, Grant I, McCutchan JA; CHARTER Group. Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation. J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):281-8. doi: 10.1097/QAI.0000000000000458.
Reference Type
BACKGROUND
Kim DJ, Westfall AO, Chamot E, Willig AL, Mugavero MJ, Ritchie C, Burkholder GA, Crane HM, Raper JL, Saag MS, Willig JH. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):600-5. doi: 10.1097/QAI.0b013e31827303d5.
Reference Type
BACKGROUND
Zheng B, Leader JK, McMurray JM, Park SC, Fuhrman CR, Gur D, Sciurba FC. Automated detection and quantitative assessment of pulmonary airways depicted on CT images. Med Phys. 2007 Jul;34(7):2844-52. doi: 10.1118/1.2742777.
Reference Type
BACKGROUND
Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest. 1999 Oct;104(8):1001-6. doi: 10.1172/JCI8124. No abstract available.
Reference Type
BACKGROUND
Aysola RS, Hoffman EA, Gierada D, Wenzel S, Cook-Granroth J, Tarsi J, Zheng J, Schechtman KB, Ramkumar TP, Cochran R, Xueping E, Christie C, Newell J, Fain S, Altes TA, Castro M. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest. 2008 Dec;134(6):1183-1191. doi: 10.1378/chest.07-2779. Epub 2008 Jul 18.
Reference Type
BACKGROUND
Montaudon M, Lederlin M, Reich S, Begueret H, Tunon-de-Lara JM, Marthan R, Berger P, Laurent F. Bronchial measurements in patients with asthma: comparison of quantitative thin-section CT findings with those in healthy subjects and correlation with pathologic findings. Radiology. 2009 Dec;253(3):844-53. doi: 10.1148/radiol.2533090303. Epub 2009 Sep 29.
Reference Type
BACKGROUND
Kosciuch J, Krenke R, Gorska K, Zukowska M, Maskey-Warzechowska M, Chazan R. Airway dimensions in asthma and COPD in high resolution computed tomography: can we see the difference? Respir Care. 2013 Aug;58(8):1335-42. doi: 10.4187/respcare.02175. Epub 2013 Jan 9.
Reference Type
BACKGROUND
Kurashima K, Hoshi T, Takayanagi N, Takaku Y, Kagiyama N, Ohta C, Fujimura M, Sugita Y. Airway dimensions and pulmonary function in chronic obstructive pulmonary disease and bronchial asthma. Respirology. 2012 Jan;17(1):79-86. doi: 10.1111/j.1440-1843.2011.02052.x.
Reference Type
BACKGROUND
Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012 May 4;18(5):716-25. doi: 10.1038/nm.2678.
Reference Type
BACKGROUND
Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009 Sep 1;180(5):388-95. doi: 10.1164/rccm.200903-0392OC. Epub 2009 May 29.
Reference Type
BACKGROUND
Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 Aug 1;178(3):218-224. doi: 10.1164/rccm.200711-1754OC. Epub 2008 May 14.
Reference Type
BACKGROUND
Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23. doi: 10.1164/rccm.200906-0896OC. Epub 2009 Nov 5.
Reference Type
BACKGROUND
Sutherland ER, Goleva E, King TS, Lehman E, Stevens AD, Jackson LP, Stream AR, Fahy JV, Leung DY; Asthma Clinical Research Network. Cluster analysis of obesity and asthma phenotypes. PLoS One. 2012;7(5):e36631. doi: 10.1371/journal.pone.0036631. Epub 2012 May 11.
Reference Type
BACKGROUND
Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006 Mar;27(3):495-503. doi: 10.1183/09031936.06.00077205.
Reference Type
BACKGROUND
Appleton SL, Adams RJ, Wilson DH, Taylor AW, Ruffin RE; North West Adelaide Health Study Team. Central obesity is associated with nonatopic but not atopic asthma in a representative population sample. J Allergy Clin Immunol. 2006 Dec;118(6):1284-91. doi: 10.1016/j.jaci.2006.08.011. Epub 2006 Nov 7.
Reference Type
BACKGROUND
Holguin F, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Erzurum SC, Fitzpatrick AM, Gaston B, Israel E, Jarjour NN, Moore WC, Peters SP, Yonas M, Teague WG, Wenzel SE. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol. 2011 Jun;127(6):1486-93.e2. doi: 10.1016/j.jaci.2011.03.036.
Reference Type
BACKGROUND
Komakula S, Khatri S, Mermis J, Savill S, Haque S, Rojas M, Brown L, Teague GW, Holguin F. Body mass index is associated with reduced exhaled nitric oxide and higher exhaled 8-isoprostanes in asthmatics. Respir Res. 2007 Apr 16;8(1):32. doi: 10.1186/1465-9921-8-32.
Reference Type
BACKGROUND
Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, Imaizumi T. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res. 2003 Feb 7;92(2):226-33. doi: 10.1161/01.res.0000052990.68216.ef.
Reference Type
BACKGROUND
Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20 Suppl 12:S60-2. doi: 10.1097/00005344-199204002-00018.
Reference Type
BACKGROUND
Palomo I, Contreras A, Alarcon LM, Leiva E, Guzman L, Mujica V, Icaza G, Diaz N, Gonzalez DR, Moore-Carrasco R. Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. Nitric Oxide. 2011 May 31;24(4):224-8. doi: 10.1016/j.niox.2011.03.002. Epub 2011 Mar 17.
Reference Type
BACKGROUND
Comhair SA, Ricci KS, Arroliga M, Lara AR, Dweik RA, Song W, Hazen SL, Bleecker ER, Busse WW, Chung KF, Gaston B, Hastie A, Hew M, Jarjour N, Moore W, Peters S, Teague WG, Wenzel SE, Erzurum SC. Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma. Am J Respir Crit Care Med. 2005 Aug 1;172(3):306-13. doi: 10.1164/rccm.200502-180OC. Epub 2005 May 5.
Reference Type
BACKGROUND
Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation. 2005 Feb;29(1):23-32. doi: 10.1007/s10753-006-8965-3.
Reference Type
BACKGROUND
Klein E, Weigel J, Buford MC, Holian A, Wells SM. Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma. Am J Physiol Lung Cell Mol Physiol. 2010 Dec;299(6):L816-25. doi: 10.1152/ajplung.00188.2010. Epub 2010 Oct 1.
Reference Type
BACKGROUND
Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998 Nov 3;98(18):1842-7. doi: 10.1161/01.cir.98.18.1842.
Reference Type
BACKGROUND
Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999 Mar 9;99(9):1141-6. doi: 10.1161/01.cir.99.9.1141.
Reference Type
BACKGROUND
Scott JA, North ML, Rafii M, Huang H, Pencharz P, Subbarao P, Belik J, Grasemann H. Asymmetric dimethylarginine is increased in asthma. Am J Respir Crit Care Med. 2011 Oct 1;184(7):779-85. doi: 10.1164/rccm.201011-1810OC.
Reference Type
BACKGROUND
Heijink I, van Oosterhout A, Kliphuis N, Jonker M, Hoffmann R, Telenga E, Klooster K, Slebos DJ, ten Hacken N, Postma D, van den Berge M. Oxidant-induced corticosteroid unresponsiveness in human bronchial epithelial cells. Thorax. 2014 Jan;69(1):5-13. doi: 10.1136/thoraxjnl-2013-203520. Epub 2013 Aug 26.
Reference Type
BACKGROUND
Baker JV, Neuhaus J, Duprez D, Freiberg M, Bernardino JI, Badley AD, Nixon DE, Lundgren JD, Tracy RP, Neaton JD; INSIGHT SMART Study Group. HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):128-34. doi: 10.1097/QAI.0b013e318252f99f.
Reference Type
BACKGROUND
Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D. Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral therapy. Antivir Ther. 2012;17(6):1021-7. doi: 10.3851/IMP2304. Epub 2012 Aug 15.
Reference Type
BACKGROUND
Parikh RV, Scherzer R, Grunfeld C, Nitta EM, Leone A, Martin JN, Deeks SG, Ganz P, Hsue PY. Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals. Atherosclerosis. 2013 Jul;229(1):246-52. doi: 10.1016/j.atherosclerosis.2013.04.025. Epub 2013 Apr 30.
Reference Type
BACKGROUND
Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D. Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res. 2009 Dec;60(6):508-14. doi: 10.1016/j.phrs.2009.07.009. Epub 2009 Aug 3.
Reference Type
BACKGROUND
Jang JJ, Berkheimer SB, Merchant M, Krishnaswami A. Asymmetric dimethylarginine and coronary artery calcium scores are increased in patients infected with human immunodeficiency virus. Atherosclerosis. 2011 Aug;217(2):514-7. doi: 10.1016/j.atherosclerosis.2011.03.035. Epub 2011 Apr 5.
Reference Type
BACKGROUND
Gingo MR, He J, Wittman C, Fuhrman C, Leader JK, Kessinger C, Lucht L, Slivka WA, Zhang Y, McMahon DK, Sciurba FC, Morris A. Contributors to diffusion impairment in HIV-infected persons. Eur Respir J. 2014 Jan;43(1):195-203. doi: 10.1183/09031936.00157712. Epub 2013 Feb 21.
Reference Type
BACKGROUND
Morris A, Gingo MR, George MP, Lucht L, Kessinger C, Singh V, Hillenbrand M, Busch M, McMahon D, Norris KA, Champion HC, Gladwin MT, Zhang Y, Steele C, Sciurba FC. Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era. AIDS. 2012 Mar 27;26(6):731-40. doi: 10.1097/QAD.0b013e32835099ae.
Reference Type
BACKGROUND
Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999 Sep;160(3):1001-8. doi: 10.1164/ajrccm.160.3.9812110.
Reference Type
BACKGROUND
Wenzel SE, Wang L, Pirozzi G. Dupilumab in persistent asthma. N Engl J Med. 2013 Sep 26;369(13):1276. doi: 10.1056/NEJMc1309809. No abstract available.
Reference Type
BACKGROUND
Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011 Jun 19;25(10):1281-8. doi: 10.1097/QAD.0b013e328347f3f1.
Reference Type
BACKGROUND
Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10.
Reference Type
BACKGROUND
Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014 Jul 23-30;312(4):380-9. doi: 10.1001/jama.2014.8334.
Reference Type
BACKGROUND
Ochiai M, Hayashi T, Morita M, Ina K, Maeda M, Watanabe F, Morishita K. Short-term effects of L-citrulline supplementation on arterial stiffness in middle-aged men. Int J Cardiol. 2012 Mar 8;155(2):257-61. doi: 10.1016/j.ijcard.2010.10.004. Epub 2010 Nov 9.
Reference Type
BACKGROUND
de Gouw HW, Verbruggen MB, Twiss IM, Sterk PJ. Effect of oral L-arginine on airway hyperresponsiveness to histamine in asthma. Thorax. 1999 Nov;54(11):1033-5. doi: 10.1136/thx.54.11.1033.
Reference Type
BACKGROUND
Kilpelainen M, Terho EO, Helenius H, Koskenvuo M. Validation of a new questionnaire on asthma, allergic rhinitis, and conjunctivitis in young adults. Allergy. 2001 May;56(5):377-84. doi: 10.1034/j.1398-9995.2001.056005377.x.
Reference Type
BACKGROUND
Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000 Jan;161(1):309-29. doi: 10.1164/ajrccm.161.1.ats11-99. No abstract available.
Reference Type
BACKGROUND
New NHLBI guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute. Lippincott Health Promot Lett. 1997 Aug;2(7):1, 8-9. No abstract available.
Reference Type
BACKGROUND
Zhu Z, Lee CG, Zheng T, Chupp G, Wang J, Homer RJ, Noble PW, Hamid Q, Elias JA. Airway inflammation and remodeling in asthma. Lessons from interleukin 11 and interleukin 13 transgenic mice. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 2):S67-70. doi: 10.1164/ajrccm.164.supplement_2.2106070.
Reference Type
BACKGROUND
Kaminska M, Foley S, Maghni K, Storness-Bliss C, Coxson H, Ghezzo H, Lemiere C, Olivenstein R, Ernst P, Hamid Q, Martin J. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol. 2009 Jul;124(1):45-51.e1-4. doi: 10.1016/j.jaci.2009.03.049. Epub 2009 May 29.
Reference Type
BACKGROUND
Lemiere C, Ernst P, Olivenstein R, Yamauchi Y, Govindaraju K, Ludwig MS, Martin JG, Hamid Q. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol. 2006 Nov;118(5):1033-9. doi: 10.1016/j.jaci.2006.08.003. Epub 2006 Sep 25.
Reference Type
BACKGROUND
Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, Ernst P, Ludwig MS, Martin JG, Hamid Q. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol. 2005 Sep;116(3):544-9. doi: 10.1016/j.jaci.2005.06.011.
Reference Type
BACKGROUND
Chu HW, Halliday JL, Martin RJ, Leung DY, Szefler SJ, Wenzel SE. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med. 1998 Dec;158(6):1936-44. doi: 10.1164/ajrccm.158.6.9712073.
Reference Type
BACKGROUND
Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ, Williams KC. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis. 2011 Jul 1;204(1):154-63. doi: 10.1093/infdis/jir214.
Reference Type
BACKGROUND
Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, Lewin SR, Jaworowski A, Crowe SM. Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One. 2011;6(5):e19968. doi: 10.1371/journal.pone.0019968. Epub 2011 May 20.
Reference Type
BACKGROUND
McDonald B, Moyo S, Gabaitiri L, Gaseitsiwe S, Bussmann H, Koethe JR, Musonda R, Makhema J, Novitsky V, Marlink RG, Wester CW, Essex M. Persistently elevated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses. 2013 Jul;29(7):993-9. doi: 10.1089/aid.2012.0309. Epub 2013 May 9.
Reference Type
BACKGROUND
O'Connor KS, Osborn L, Olson L, Blumberg SJ, Frankel MR, Srinath KP, Giambo P. Design and operation of the National Asthma Survey. Vital Health Stat 1. 2008 Aug;(46):1-122.
Reference Type
BACKGROUND
Juniper EF, Svensson K, Mork AC, Stahl E. Measuring health-related quality of life in adults during an acute asthma exacerbation. Chest. 2004 Jan;125(1):93-7. doi: 10.1378/chest.125.1.93.
Reference Type
BACKGROUND
Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet. 1965 Apr 10;1(7389):775-9. No abstract available.
Reference Type
BACKGROUND
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68. doi: 10.1183/09031936.05.00035205. No abstract available.
Reference Type
BACKGROUND
Wang Z, Gu S, Leader JK, Kundu S, Tedrow JR, Sciurba FC, Gur D, Siegfried JM, Pu J. Optimal threshold in CT quantification of emphysema. Eur Radiol. 2013 Apr;23(4):975-84. doi: 10.1007/s00330-012-2683-z. Epub 2012 Nov 1.
Reference Type
BACKGROUND
Nakano Y, Wong JC, de Jong PA, Buzatu L, Nagao T, Coxson HO, Elliott WM, Hogg JC, Pare PD. The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med. 2005 Jan 15;171(2):142-6. doi: 10.1164/rccm.200407-874OC. Epub 2004 Oct 29.
Reference Type
BACKGROUND
Patel BD, Coxson HO, Pillai SG, Agusti AG, Calverley PM, Donner CF, Make BJ, Muller NL, Rennard SI, Vestbo J, Wouters EF, Hiorns MP, Nakano Y, Camp PG, Nasute Fauerbach PV, Screaton NJ, Campbell EJ, Anderson WH, Pare PD, Levy RD, Lake SL, Silverman EK, Lomas DA; International COPD Genetics Network. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Sep 1;178(5):500-5. doi: 10.1164/rccm.200801-059OC. Epub 2008 Jun 19.
Reference Type
BACKGROUND
Murphy RA, Reinders I, Register TC, Ayonayon HN, Newman AB, Satterfield S, Goodpaster BH, Simonsick EM, Kritchevsky SB, Harris TB. Associations of BMI and adipose tissue area and density with incident mobility limitation and poor performance in older adults. Am J Clin Nutr. 2014 May;99(5):1059-65. doi: 10.3945/ajcn.113.080796. Epub 2014 Feb 12.
Reference Type
BACKGROUND
Veraldi KL, Gibson BT, Yasuoka H, Myerburg MM, Kelly EA, Balzar S, Jarjour NN, Pilewski JM, Wenzel SE, Feghali-Bostwick CA. Role of insulin-like growth factor binding protein-3 in allergic airway remodeling. Am J Respir Crit Care Med. 2009 Oct 1;180(7):611-7. doi: 10.1164/rccm.200810-1555OC. Epub 2009 Jul 16.
Reference Type
BACKGROUND
Chu HW, Balzar S, Seedorf GJ, Westcott JY, Trudeau JB, Silkoff P, Wenzel SE. Transforming growth factor-beta2 induces bronchial epithelial mucin expression in asthma. Am J Pathol. 2004 Oct;165(4):1097-106. doi: 10.1016/s0002-9440(10)63371-8.
Reference Type
BACKGROUND
Moore WC, Evans MD, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, Erzurum SC, Curran-Everett D, Dweik RA, Gaston B, Hew M, Israel E, Mayse ML, Pascual RM, Peters SP, Silveira L, Wenzel SE, Jarjour NN; National Heart, Lung, and Blood Institute's Severe Asthma Research Group. Safety of investigative bronchoscopy in the Severe Asthma Research Program. J Allergy Clin Immunol. 2011 Aug;128(2):328-336.e3. doi: 10.1016/j.jaci.2011.02.042. Epub 2011 Apr 15.
Reference Type
BACKGROUND
Vanderweele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol. 2010 Dec 15;172(12):1339-48. doi: 10.1093/aje/kwq332. Epub 2010 Oct 29.
Reference Type
BACKGROUND
Vittinghoff E, Sen S, McCulloch CE. Sample size calculations for evaluating mediation. Stat Med. 2009 Feb 15;28(4):541-57. doi: 10.1002/sim.3491.
Reference Type
BACKGROUND
Poirier CD, Inhaber N, Lalonde RG, Ernst P. Prevalence of bronchial hyperresponsiveness among HIV-infected men. Am J Respir Crit Care Med. 2001 Aug 15;164(4):542-5. doi: 10.1164/ajrccm.164.4.2010019.
Reference Type
BACKGROUND
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003 Dec;112(12):1796-808. doi: 10.1172/JCI19246.
Reference Type
BACKGROUND
Lugogo NL, Hollingsworth JW, Howell DL, Que LG, Francisco D, Church TD, Potts-Kant EN, Ingram JL, Wang Y, Jung SH, Kraft M. Alveolar macrophages from overweight/obese subjects with asthma demonstrate a proinflammatory phenotype. Am J Respir Crit Care Med. 2012 Sep 1;186(5):404-11. doi: 10.1164/rccm.201109-1671OC. Epub 2012 Jul 5.
Reference Type
BACKGROUND
Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep. 2008 Feb;10(1):61-70. doi: 10.1007/s11883-008-0010-6.
Reference Type
BACKGROUND
Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995 Dec 15;270(5243):1811-5. doi: 10.1126/science.270.5243.1811.
Reference Type
BACKGROUND
Belda J, Leigh R, Parameswaran K, O'Byrne PM, Sears MR, Hargreave FE. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):475-8. doi: 10.1164/ajrccm.161.2.9903097.
Reference Type
BACKGROUND
Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB, Bianchi A, Michetti G. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1172-4. doi: 10.1164/ajrccm.162.3.9908057.
Reference Type
BACKGROUND
Mallon PW, Sedwell R, Rogers G, Nolan D, Unemori P, Hoy J, Samaras K, Kelleher A, Emery S, Cooper DA, Carr A; Rosey Investigators. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis. 2008 Dec 15;198(12):1794-803. doi: 10.1086/593179.
Reference Type
BACKGROUND
Kerzerho J, Maazi H, Speak AO, Szely N, Lombardi V, Khoo B, Geryak S, Lam J, Soroosh P, Van Snick J, Akbari O. Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity. J Allergy Clin Immunol. 2013 Apr;131(4):1048-57, 1057.e1-2. doi: 10.1016/j.jaci.2012.09.027. Epub 2012 Nov 20.
Reference Type
BACKGROUND
McLaughlin T, Stuhlinger M, Lamendola C, Abbasi F, Bialek J, Reaven GM, Tsao PS. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab. 2006 May;91(5):1896-900. doi: 10.1210/jc.2005-1441. Epub 2006 Feb 28.
Reference Type
BACKGROUND
Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003 Dec;4(4):33-40. doi: 10.1016/s1567-5688(03)00032-1.
Reference Type
BACKGROUND
Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem. 1997 Jul;43(7):1209-14.
Reference Type
BACKGROUND
Maiolino G, Rossitto G, Caielli P, Bisogni V, Rossi GP, Calo LA. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm. 2013;2013:714653. doi: 10.1155/2013/714653. Epub 2013 Oct 3.
Reference Type
BACKGROUND
Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002 Apr 15;303(2):131-7. doi: 10.1006/abio.2001.5575.
Reference Type
BACKGROUND
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov 2;382(9903):1525-33. doi: 10.1016/S0140-6736(13)61809-7. Epub 2013 Oct 23.
Reference Type
BACKGROUND
Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000 Nov 9;408(6809):239-47. doi: 10.1038/35041687.
Reference Type
BACKGROUND
Modena BD, Tedrow JR, Milosevic J, Bleecker ER, Meyers DA, Wu W, Bar-Joseph Z, Erzurum SC, Gaston BM, Busse WW, Jarjour NN, Kaminski N, Wenzel SE. Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. Am J Respir Crit Care Med. 2014 Dec 15;190(12):1363-72. doi: 10.1164/rccm.201406-1099OC.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO15070529
Identifier Type: -
Identifier Source: org_study_id